Pharmacology Substudies of A5263 and A5264
Sponsors:
US National Institute of Allergy and Infectious Diseases (NIAID)
The National Cancer Institute (NCI)
National Institute on Dental Craniofacial Research (NIDCR)
Protocol Summary:
A5278 is designed to assess the direction and magnitude of pharmacokinetic (PK) interactions between the antiretroviral agents efavirenz/tenofovir/emtricitabine (EFV/TDF/FTC) and the Karbosi’s sarcoma (KS) chemotherapy agents etoposide (ET), vincristine (VCR), and paclitaxel (PTX).
Years: 2013 – 2014
Investigator: Margaret Borok-Williams, MD, CHB, MMED
Location: Parirenyatwa CRS
ACTG
Completed Study
Publication:
Comments are closed.